Cargando…

Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis after Conservative Treatment for Symptomatic Bile Duct Stones

INTRODUCTION: Endoscopic retrograde cholangiopancreatography (ERCP) for asymptomatic common bile duct stones (CBDS) has been associated with an increased risk of post-ERCP pancreatitis (PEP). Patients with asymptomatic CBDS at the time of ERCP include those with incidentally discovered CBDS (group A...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Hirokazu, Kadono, Yoshihiro, Shono, Takashi, Kamikawa, Kentaro, Urata, Atsushi, Nasu, Jiro, Uehara, Masayoshi, Matsushita, Ikuo, Kakuma, Tatsuyuki, Tada, Shuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japan Medical Association 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169264/
https://www.ncbi.nlm.nih.gov/pubmed/37179718
http://dx.doi.org/10.31662/jmaj.2022-0165
_version_ 1785039019144380416
author Saito, Hirokazu
Kadono, Yoshihiro
Shono, Takashi
Kamikawa, Kentaro
Urata, Atsushi
Nasu, Jiro
Uehara, Masayoshi
Matsushita, Ikuo
Kakuma, Tatsuyuki
Tada, Shuji
author_facet Saito, Hirokazu
Kadono, Yoshihiro
Shono, Takashi
Kamikawa, Kentaro
Urata, Atsushi
Nasu, Jiro
Uehara, Masayoshi
Matsushita, Ikuo
Kakuma, Tatsuyuki
Tada, Shuji
author_sort Saito, Hirokazu
collection PubMed
description INTRODUCTION: Endoscopic retrograde cholangiopancreatography (ERCP) for asymptomatic common bile duct stones (CBDS) has been associated with an increased risk of post-ERCP pancreatitis (PEP). Patients with asymptomatic CBDS at the time of ERCP include those with incidentally discovered CBDS (group A) and previously symptomatic patients with CBDS who became asymptomatic after conservative treatment for symptomatic CBDS, including obstructive jaundice or acute cholangitis (group B). In this study, we aimed to examine PEP risk in group B by comparing PEP risks between groups A, B, and currently symptomatic patients (group C). METHODS: In this multicenter retrospective study, we examined 77 patients in group A, 41 patients in group B, and 1225 patients in group C who had native papillae. PEP incidence rates between asymptomatic patients at the time of ERCP (groups A and B) and symptomatic patients (group C) were compared using one-to-one propensity score matching. Bonferroni’s correction analysis was also performed to compare PEP incidence rates among the three groups. RESULTS: As per our findings, PEP incidence rate in propensity score-matched groups A and B was significantly higher than that of propensity score-matched group C (13.2% [15/114] versus 4.4% [5/114], respectively, P = 0.033). In groups A and B, PEP incidence rates were 11.7% (9/77) and 14.6% (6/41), respectively. PEP risk in group B was similar to that in group A (P = 1.0). PEP incidence in group B was significantly higher than PEP incidence in group C (14.6% (6/41)) vs. 2.9% (35/1225)) (P = 0.005)). CONCLUSIONS: ERCP for previously symptomatic patients with CBDS who became asymptomatic after conservative treatment for symptomatic CBDS may increase the risk of PEP compared with ERCP for currently symptomatic patients. Thus, ERCP should be performed before patients become asymptomatic using conservative treatments if patients can tolerate ERCP procedures.
format Online
Article
Text
id pubmed-10169264
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Japan Medical Association
record_format MEDLINE/PubMed
spelling pubmed-101692642023-05-10 Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis after Conservative Treatment for Symptomatic Bile Duct Stones Saito, Hirokazu Kadono, Yoshihiro Shono, Takashi Kamikawa, Kentaro Urata, Atsushi Nasu, Jiro Uehara, Masayoshi Matsushita, Ikuo Kakuma, Tatsuyuki Tada, Shuji JMA J Original Research Article INTRODUCTION: Endoscopic retrograde cholangiopancreatography (ERCP) for asymptomatic common bile duct stones (CBDS) has been associated with an increased risk of post-ERCP pancreatitis (PEP). Patients with asymptomatic CBDS at the time of ERCP include those with incidentally discovered CBDS (group A) and previously symptomatic patients with CBDS who became asymptomatic after conservative treatment for symptomatic CBDS, including obstructive jaundice or acute cholangitis (group B). In this study, we aimed to examine PEP risk in group B by comparing PEP risks between groups A, B, and currently symptomatic patients (group C). METHODS: In this multicenter retrospective study, we examined 77 patients in group A, 41 patients in group B, and 1225 patients in group C who had native papillae. PEP incidence rates between asymptomatic patients at the time of ERCP (groups A and B) and symptomatic patients (group C) were compared using one-to-one propensity score matching. Bonferroni’s correction analysis was also performed to compare PEP incidence rates among the three groups. RESULTS: As per our findings, PEP incidence rate in propensity score-matched groups A and B was significantly higher than that of propensity score-matched group C (13.2% [15/114] versus 4.4% [5/114], respectively, P = 0.033). In groups A and B, PEP incidence rates were 11.7% (9/77) and 14.6% (6/41), respectively. PEP risk in group B was similar to that in group A (P = 1.0). PEP incidence in group B was significantly higher than PEP incidence in group C (14.6% (6/41)) vs. 2.9% (35/1225)) (P = 0.005)). CONCLUSIONS: ERCP for previously symptomatic patients with CBDS who became asymptomatic after conservative treatment for symptomatic CBDS may increase the risk of PEP compared with ERCP for currently symptomatic patients. Thus, ERCP should be performed before patients become asymptomatic using conservative treatments if patients can tolerate ERCP procedures. Japan Medical Association 2023-03-13 2023-04-14 /pmc/articles/PMC10169264/ /pubmed/37179718 http://dx.doi.org/10.31662/jmaj.2022-0165 Text en Copyright © Japan Medical Association https://creativecommons.org/licenses/by/4.0/JMA Journal is an Open Access journal distributed under the Creative Commons Attribution 4.0 International License. To view the details of this license, please visit (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Original Research Article
Saito, Hirokazu
Kadono, Yoshihiro
Shono, Takashi
Kamikawa, Kentaro
Urata, Atsushi
Nasu, Jiro
Uehara, Masayoshi
Matsushita, Ikuo
Kakuma, Tatsuyuki
Tada, Shuji
Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis after Conservative Treatment for Symptomatic Bile Duct Stones
title Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis after Conservative Treatment for Symptomatic Bile Duct Stones
title_full Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis after Conservative Treatment for Symptomatic Bile Duct Stones
title_fullStr Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis after Conservative Treatment for Symptomatic Bile Duct Stones
title_full_unstemmed Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis after Conservative Treatment for Symptomatic Bile Duct Stones
title_short Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis after Conservative Treatment for Symptomatic Bile Duct Stones
title_sort post-endoscopic retrograde cholangiopancreatography pancreatitis after conservative treatment for symptomatic bile duct stones
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169264/
https://www.ncbi.nlm.nih.gov/pubmed/37179718
http://dx.doi.org/10.31662/jmaj.2022-0165
work_keys_str_mv AT saitohirokazu postendoscopicretrogradecholangiopancreatographypancreatitisafterconservativetreatmentforsymptomaticbileductstones
AT kadonoyoshihiro postendoscopicretrogradecholangiopancreatographypancreatitisafterconservativetreatmentforsymptomaticbileductstones
AT shonotakashi postendoscopicretrogradecholangiopancreatographypancreatitisafterconservativetreatmentforsymptomaticbileductstones
AT kamikawakentaro postendoscopicretrogradecholangiopancreatographypancreatitisafterconservativetreatmentforsymptomaticbileductstones
AT urataatsushi postendoscopicretrogradecholangiopancreatographypancreatitisafterconservativetreatmentforsymptomaticbileductstones
AT nasujiro postendoscopicretrogradecholangiopancreatographypancreatitisafterconservativetreatmentforsymptomaticbileductstones
AT ueharamasayoshi postendoscopicretrogradecholangiopancreatographypancreatitisafterconservativetreatmentforsymptomaticbileductstones
AT matsushitaikuo postendoscopicretrogradecholangiopancreatographypancreatitisafterconservativetreatmentforsymptomaticbileductstones
AT kakumatatsuyuki postendoscopicretrogradecholangiopancreatographypancreatitisafterconservativetreatmentforsymptomaticbileductstones
AT tadashuji postendoscopicretrogradecholangiopancreatographypancreatitisafterconservativetreatmentforsymptomaticbileductstones